Comparative efficacy of Helicobacter pylori eradication therapy between tegoprazan‐based concomitant and bismuth quadruple therapies: A real‐world evidence

相伴的 医学 幽门螺杆菌 内科学 不利影响 克拉霉素 胃肠病学 质子抑制剂泵 置信区间 联合疗法 外科 材料科学 冶金
作者
Yoon Suk Jung,Byung Wook Jung,Chan Hyuk Park
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
被引量:1
标识
DOI:10.1111/jgh.16798
摘要

Abstract Background and Aim Tegoprazan, a potassium‐competitive acid blocker, can be used as a substitute for proton pump inhibitors in Helicobacter pylori eradication therapy; some studies have reported improved efficacy. In Korea, where clarithromycin resistance rates are high, we aimed to compare the efficacies of tegoprazan‐based concomitant and bismuth quadruple therapies. Methods We retrospectively analyzed data from patients with H. pylori infection who received either 10‐day tegoprazan‐based concomitant therapy or 14‐day tegoprazan‐based bismuth quadruple therapy as first‐line treatment. The primary outcome was H. pylori eradication rate, with secondary outcomes including adverse events and insufficient medication rates. Results Among the 1082 patients included in the study, 620 and 462 were treated with tegoprazan‐based concomitant and bismuth quadruple therapies, respectively. Intention‐to‐treat analysis demonstrated no difference in eradication rates between the tegoprazan‐based concomitant and bismuth quadruple therapy groups (74.7% [95% confidence interval—CI, 71.1–78.0%] vs 74.7% [95% CI, 70.6–78.5%], P = 0.999). Per‐protocol analysis also showed similar eradication rates between the two groups (88.0% [95% CI, 85.0–90.6%] vs 89.7% [95% CI, 86.3–92.5%], P = 0.424). The overall adverse event rates (49.6% vs 39.2%, P = 0.001) and insufficient medication rates (4.8% vs 2.4%, P = 0.036) were higher in the bismuth quadruple therapy group than in the concomitant therapy group. Conclusions The eradication rates of tegoprazan‐based 10‐day concomitant therapy and 14‐day bismuth quadruple therapy were comparable. However, because of its shorter treatment duration, better medical adherence, and lower incidence of adverse events, tegoprazan‐based concomitant therapy may be preferable in regions with high rates of clarithromycin and metronidazole resistance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
靖123456发布了新的文献求助10
刚刚
拓跋箴完成签到,获得积分10
刚刚
彭于晏应助zy采纳,获得10
1秒前
精明玲完成签到 ,获得积分10
2秒前
2秒前
乐乐完成签到,获得积分10
3秒前
VirSnorlax完成签到,获得积分10
3秒前
SciGPT应助LL采纳,获得10
3秒前
妖孽宇发布了新的文献求助10
4秒前
aa完成签到,获得积分20
4秒前
aaaa完成签到,获得积分10
4秒前
马香芦完成签到,获得积分10
5秒前
西红柿完成签到,获得积分10
6秒前
7秒前
懵懂的冬灵完成签到,获得积分10
7秒前
碧蓝可仁完成签到 ,获得积分10
8秒前
王拉拉完成签到 ,获得积分10
8秒前
西西完成签到,获得积分10
8秒前
深情安青应助mkmimii采纳,获得10
9秒前
上官若男应助小王采纳,获得10
9秒前
bkagyin应助旦皋采纳,获得10
9秒前
Orange应助欣欣采纳,获得10
10秒前
玄学大哥完成签到,获得积分10
10秒前
10秒前
10秒前
kk完成签到,获得积分10
10秒前
ww007完成签到,获得积分10
12秒前
科研通AI5应助hahaha123213123采纳,获得10
12秒前
misstwo完成签到,获得积分10
13秒前
研友_ZzrwqZ发布了新的文献求助10
13秒前
JY'完成签到,获得积分10
14秒前
一只小鲨鱼完成签到,获得积分10
15秒前
漂亮的哈密瓜完成签到,获得积分10
15秒前
量子星尘发布了新的文献求助10
15秒前
16秒前
LL发布了新的文献求助10
16秒前
苏苏完成签到,获得积分10
17秒前
17秒前
fabc5653219完成签到,获得积分10
18秒前
hkunyu完成签到 ,获得积分10
18秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029